Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues

On 27 May 2022 the FDA published the final guidance for industry.

This guidance describes the FDA’s current recommendations regarding the overall development program to establish the effectiveness and safety of gonadotropin-releasing hormone (GnRH) analogues for treating advanced prostate cancer.

Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /